Skip to main content
AGTX
OTC Life Sciences

Agentix Corp. Discloses Going Concern Doubt, Ineffective Controls, and Critical Liquidity Issues

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.042
Mkt Cap
$1.682M
52W Low
$0.017
52W High
$1.24
Market data snapshot near publication time

summarizeSummary

Agentix Corp. filed its 10-Q, revealing substantial doubt about its ability to continue as a going concern, critically low cash reserves, and ineffective disclosure controls, highlighting severe financial and operational challenges.


check_boxKey Events

  • Going Concern Warning Issued

    The company explicitly stated that its accumulated deficit, net loss, negative operating cash flows, and negative working capital raise substantial doubt about its ability to continue as a going concern.

  • Critical Liquidity Position

    Agentix Corp. reported only $6,396 in cash on hand as of December 31, 2025, which is insufficient to support daily operations and necessitates immediate additional funding.

  • Ineffective Disclosure Controls

    Management concluded that the company's disclosure controls and procedures were not effective as of December 31, 2025, indicating a material weakness in internal financial reporting.

  • Increased Net Loss and Cash Burn

    The company's net loss for the nine months ended December 31, 2025, worsened to $408,526, compared to $385,280 in the prior year, with cash used in operating activities increasing to $123,305.


auto_awesomeAnalysis

Agentix Corp.'s latest 10-Q filing presents a highly concerning financial outlook, explicitly stating substantial doubt about its ability to continue as a going concern. The company's cash reserves are critically low at just $6,396, insufficient to support daily operations, and it continues to experience negative cash flows from operating activities. This severe liquidity crisis is compounded by a significant reliance on related party debt, which is secured by all company assets and carries a high interest rate. Furthermore, management concluded that the company's disclosure controls and procedures were ineffective, indicating a material weakness in financial reporting oversight. These factors collectively point to extreme financial distress and significant operational risks, necessitating immediate and substantial funding to avoid failure.

At the time of this filing, AGTX was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.02 to $1.24. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed AGTX - Latest Insights

AGTX
Feb 17, 2026, 1:26 PM EST
Filing Type: 10-Q
Importance Score:
9